EUVIMEDEUVIMED entdecken
Crossref

Kui‐Jie‐Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota

Kun Li, Lengqiu Guo, Jinghua Yu, Yun Yang, Lan Wei, Chunyan Min, Xinkang Xu, Fang Li, Jiangyun Liu, Guangquan Zhou, Jian Zhang iD

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Kun Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Haian Hospital of Traditional Chinese Medicine, Nantong, China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Gastrointestinal Microbiome, Disease Models, Animal, Adalimumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Suzhou Science and Technology Planning Project in Jiangsu Province of China, Jiangsu Health Commission Medical Research Projects, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Kui‐Jie‐Ling capsule (Kui‐Jie‐Ling) is a hospital preparation for ulcerative colitis (UC) in China. This study aimed at evaluating the protective effects and mechanisms of Kui‐Jie‐Ling and Kui‐Jie‐Ling combined with adalimumab on UC induced by dextran sulfate sodium (DSS).

Methods

Network pharmacology was combined with an animal experiment to reveal the targets of Kui‐Jie‐Ling alleviating UC. The UC model was established by drinking 2.5% DSS solution for 7 days. On the second day, the mice in the Kui‐Jie‐Ling group were orally administered with Kui‐Jie‐Ling (1.5 and 3.0 g/kg) daily for seven consecutive days, and the mice in the combination group were orally administered with Kui‐Jie‐Ling (3.0 g/kg) once a day for seven consecutive days and received one subcutaneous injection of adalimumab. The disease activity index, the colon length, the spleen index, the cytokines, the colon, the short‐chain fatty acid content, and the gut microbiota in the colon were analyzed. The role of gut microbiota against UC was verified by fecal microbiota transplantation experiments.

Results

The animal study's results were consistent with the network pharmacology analysis, which reflected that Kui‐Jie‐Ling alleviated UC via multi‐pathway. Kui‐Jie‐Ling ameliorated UC by inhibiting the formation of neutrophil extracellular traps (NETs), regulating inflammatory factors through the lipopolysaccharide–toll‐like receptor 4/nuclear factor kappa B and interleukin‐23–Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway, and restoring intestinal homeostasis.

Conclusion

These studies provided the experimental basis for the clinical administration of Kui‐Jie‐Ling and Kui‐Jie‐Ling combined with adalimumab against UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeGastrointestinal MicrobiomeDisease Models, AnimalAdalimumabDrugs, Chinese HerbalAnimalsDextran SulfateMaleCapsulesColonCytokinesFecal Microbiota TransplantationMiceMice, Inbred C57BLAnti-Inflammatory AgentsInflammationNF-kappa BDrug Therapy, Combination

Stichwörter der Autor:innen

Kui‐Jie‐Ling capsuleadalimumabcombinationulcerative colitis

Substanzen

AdalimumabDrugs, Chinese HerbalDextran SulfateCapsulesCytokinesAnti-Inflammatory AgentsNF-kappa B

Autor:innen und Institutionen

  • Department of Gastroenterology, Haian Hospital of Traditional Chinese Medicine, Nantong, China.
  • Suzhou Vocational Health College, Suzhou, China.
  • College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
  • Suzhou Institute for Food and Drug Control, Suzhou, China.

ORCID-Profile: Jian Zhang

Förderung

  • National Natural Science Foundation of China
  • Suzhou Science and Technology Planning Project in Jiangsu Province of China
  • Jiangsu Health Commission Medical Research Projects, China
  • Science and Technology Bureau of Haian City, China
  • Scientific and Technological Innovation Team Building Program of Suzhou Vocational Health College
  • Priority Academic Program Development of the Jiangsu Higher Education Institutes, China
  • Science and Technology Planning Project of Suzhou Vocational Health College

Zitieren

APA

Li, K., Guo, L., Yu, J., Yang, Y., Wei, L., Min, C., Xu, X., Li, F., Liu, J., Zhou, G., & Zhang, J. (2024). Kui‐Jie‐Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16758

Vancouver

Li K, Guo L, Yu J, Yang Y, Wei L, Min C, et al. Kui‐Jie‐Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16758

BibTeX
@article{Li2024,
  author = {Li, Kun and Guo, Lengqiu and Yu, Jinghua and Yang, Yun and Wei, Lan and Min, Chunyan and Xu, Xinkang and Li, Fang and Liu, Jiangyun and Zhou, Guangquan and Zhang, Jian},
  title = {Kui‐Jie‐Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16758}
}
Kostenlos starten →